Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Access and Evidence: Implications of the EPO Safety Debate (Part 2)

Oct 01 2007

• By Michael McCaughan

Related Content

The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit

Jun 01 2007

CMS Takes A Back Seat to No One When it Comes to Drug Safety

Oct 01 2007

Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)

Jul 01 2007

Big Pharma's Year of Big Layoffs

Sep 01 2007

Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn

Dec 01 2006

Related Companies

Amgen, Inc.

Genentech, Inc.

Additional Topics

Regulation Reimbursement Government Payers BioPharmaceutical

More from Market Access

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window